Weight Loss Treatment with Phentermine and Phendimetrazine

Introduction to Phentermine and Phendimetrazine

• The American College of Physicians recommends phentermine as a first-line sympathomimetic agent for weight loss, with a documented mean weight loss of 3.6 kg at 6 months 1
• Phentermine achieves approximately 5.1% weight loss at 28 weeks, with 46% of patients achieving ≥5% weight loss and 20.8% achieving ≥10% weight loss 3

Evidence-Based Rationale for Phentermine

• The American College of Physicians specifically lists phentermine as a recommended option for adjunctive pharmacotherapy in obesity 1
• Phentermine is FDA-approved for short-term use (a few weeks) at doses of 15-37.5 mg daily 3

Comparison of Phentermine and Phendimetrazine

• Phendimetrazine is not mentioned in any of the major obesity treatment guidelines (American College of Physicians 2005, ADA 2002, AGA 2017) 1, 2, 4
• No comparative trials directly demonstrate phendimetrazine superiority over phentermine for weight loss outcomes 1

Safety Profile Comparison

• Monitor blood pressure and heart rate at every visit throughout treatment 2, 3
• Both phentermine and phendimetrazine carry warnings about rare but serious risks of primary pulmonary hypertension and valvular heart disease 2, 3

Alternative Weight Loss Considerations

• Orlistat offers a non-stimulant mechanism (lipase inhibition) with mean weight loss of 2.89 kg at 12 months, suitable for patients with cardiovascular concerns 1, 2
• GLP-1 receptor agonists (semaglutide 2.4 mg, liraglutide 3.0 mg) provide superior weight loss efficacy (8-15%) without sympathomimetic cardiovascular effects 3